Matrix metalloproteinases (MMPs) play a major role in inflammatory processes as they degrade extracellular proteins and modify immune responses. Inflammation is the driving factor in atherogenesis and MMPs, particularly MMP-8, has been linked to atherosclerotic plaque progression. MMP-8 is shown to be strongly associated with cardiovascular diseases (CVDs) and its complications thus providing a potential marker to identify patients at risk. Previously, laborious and expensive immunofluorometric assay (IFMA) was needed to reliably detect MMP-8 levels in serum. In this study, we compared a novel in-house ELISA-assay, dentoELISA, to the standard IFMA in determination of serum MMP-8 concentrations. As a cheaper and non-laborious assay, ELISA proved to be diagnostically as sensitive and specific as the IFMA. ROC statistics showed highly similar areas under the curve for both assays (0.779 versus 0.781). Furthermore, the concentrations measured by ELISA correlated significantly with concentrations determined with IFMA (r = 0.881, P < 0.001). In our study population, MMP-8 levels were significantly higher in the acute coronary syndrome patients (n = 2071) in comparison to reference population without significant coronary artery disease (n = 653). With this background, MMP-8-ELISA could provide interesting new approaches to novel CVD diagnostics.
Keyphrases
- end stage renal disease
- coronary artery disease
- high throughput
- ejection fraction
- acute coronary syndrome
- immune response
- newly diagnosed
- chronic kidney disease
- cell migration
- cardiovascular disease
- prognostic factors
- peritoneal dialysis
- percutaneous coronary intervention
- liver failure
- patient reported outcomes
- left ventricular
- cardiovascular events
- type diabetes
- risk factors
- mass spectrometry
- metabolic syndrome
- aortic stenosis
- heart failure
- drug induced
- human health
- solid phase extraction